Commentary by Judith Brenner MD, Associate Program Director, NYU Internal Medicine Residency Program
The most recent installment in JAMA’s Rational Clinical Exam Series seeks to determine the accuracy of the history, physical exam, radiology and laboratory in making the diagnosis of osteomyelitis in diabetics. This is relevant given …
Welcome to HotSpots, a new feature of Clinical Correlations. In this series, we intend to highlight unique websites of interest to the medical profession. Feel free to make suggestions for sites that should be …
Commentary by Rosemary Adamson MD, PGY-2
Be on the look-out for measles! New York City’s Department of Health and Mental Hygiene (DOHMH) issued a measles alert at the end of last November because there were …
Commentary by Neal Steigbigel MD, Professor of Medicine (Infectious Diseases/Immunology)
Methicillin resistant Staphylococcus aureus (MRSA) was a hot topic at this year’s IDSA meeting. The CA (community-acquired)-MRSA strains are spreading rapidly …
Commentary by Urania Rappo, PGY-2
This week’s Medicine Grand Rounds guest lecturer was Dr. Robert Finberg, currently Chair of the Department of Medicine at the University of Massachusetts Medical School. He earned his …
Commentary by Helen Kourlas PharmD, Pharmacology Section Editor
On October 16th the FDA announced the approval of raltegravir (Isentress®) for the treatment of Human Immunodeficiency Virus (HIV)-1 infection in combination with other antiretroviral agents. …
Welcome to our Grand Rounds Series. Each week, we plan to post a summary of the week’s Medicine Grand Rounds lecture. The summaries are reviewed and approved by the grand rounds …
Commentary by Sumathi Sivapalasingam MD, NYU Division of Infectious Diseases
Rifaximin is an oral semi-synthetic analog of rifampin which is essentially not absorbed (bioavailability <0.4%) making it useful for the treatment of …